Evolution of serum albumin/globulin ratio after antimonial therapy in canine leishmaniasis.
Amusategui
I
I
Facultad de Veterinaria, Universidad Complutense de Madrid, Spain.
Sainz
A
A
Tesouro
M A
MA
D000493:Allopurinol / Q000627:therapeutic use; D000818:Animals; D000965:Antimony / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D004283:Dog Diseases / Q000097:blood* / Q000188:drug therapy; D004285:Dogs; D005500:Follow-Up Studies; D018314:Leishmania infantum; D007898:Leishmaniasis, Visceral / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D008536:Meglumine / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use*; D012044:Regression Analysis; D012709:Serum Albumin / Q000378:metabolism*; D012712:Serum Globulins / Q000378:metabolism*; D013997:Time Factors
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D012709:Serum Albumin; D012712:Serum Globulins; D000493:Allopurinol; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony